Photocure ASA (0IMT) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Well, good afternoon. Good morning. I'm Dan Schneider, president and CEO of Photocure. Welcome to today's presentation of second quarter twenty twenty six results. With me today is Priyam Shah, our vice president of Investor Relations, and Dick Peters, our Vice President of Finance and IT. Just a reminder that the usual disclaimers are in effect for today's presentation. So the slide you've seen before, this is Photocure's corporate strategy. It's centered on three priorities that guide execution and capital allocation. First is strengthening the core, drive disciplined growth in hex, fix, and syssue franchise by expanding blue light cystoscopy tower installations, upgrades, and The US mobile VLC adoption while increasing penetration across key markets. The second is leading the standard. Established BLC as a standard of care across non muscle invasive bladder cancer detection, surveillance and treatment monitoring through next generation high def systems, expanded market access and global flexible VLC adoption. And third, expand the platform. Build a broader uro oncology and precision diagnostic platform through biomarkers, artificial intelligence, partnerships, and strategic M and A. Recent examples include the acquisition of Vesca Health and our partnership with Arterra AI. Together, these priorities are designed to drive near term growth while strengthening our long term competitive position in non muscle invasive bladder cancer. So some highlights from Q2. Product growth overall, we had 11% product revenue growth ex FX. In North America, we delivered 12% product revenue growth minus foreign exchange and 10% unit growth. And by the way, rigid growth was 13%. The installed base of Saphira upgraded blue light equipment continued to increase with four new tower plac...